NCT07183189 2025-12-18
A Study of SHR-A2009 Combined With Aumolertinib Versus Aumolertinib for First-line Treatment in EGFR-mutated, Advanced or Metastatic NSCLC
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 3 Recruiting
Clinical Trials
36 trialsNCT06417008 2025-08-01
A Study of HS-20117 Combined With Aumolertinib in Participants With Advanced Non-Squamous Non-Small Cell Lung Cancer
Hansoh BioMedical R&D Company
Phase 2/3 Recruiting
NCT06752408 2024-12-30
ANOTHER
Peking Union Medical College Hospital
Phase 2 Not yet recruiting
NCT04923906 2024-11-25
Aumolertinib with or Without Chemotherapy As 1st Line Treatment in Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Sensitizing EGFR Mutations
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Phase 3 Active not recruiting
NCT04687241 2024-11-07
Almonertinib Versus Placebo as Adjuvant Therapy in Resected Stage II-IIIB Non-Small Cell Lung Cancer With EGFR-sensitive Mutations
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Phase 3 Active not recruiting
NCT04685070 2024-08-14
Neoadjuvant HS-10296 (Almonertinib) Therapy for Potential Resectable Stage III EGFR Mutation-Positive Non-small Cell Lung Cancer
Shanghai Pulmonary Hospital, Shanghai, China
Phase 2 Active not recruiting
NCT06463171 2024-06-17
Phase II Trial of Almonertinib Plus Lastet for EGFR+ Non-small Cell Lung Cancer
Shanghai Pulmonary Hospital, Shanghai, China
Phase 2 Not yet recruiting
NCT06452433 2024-06-11
Gumarontinib Combined With 3rd EGFR-TKI in Patients With Non-small Cell Lung Cancer.
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Not yet recruiting
NCT05493501 2024-05-02
Aumolertinib With Chemotherapy or Alone Compared With Osimertinib in Patients With Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer
EQRx International, Inc.
Phase 3 Terminated
NCT06300424 2024-04-17
NEOVADE
Guangdong Provincial People's Hospital
Phase 2 Recruiting
NCT05946460 2024-02-06
Neoadjuvant Aumolertinib in Patients With AI-diagnosed EGFR-mutant High-risk Pulmonary Ground-glass Opacity.
The First Affiliated Hospital of Guangzhou Medical University
Phase 2 Unknown
NCT06185400 2023-12-29
RC48 Combined With EGFR or HER2 TKI for Locally Advanced or Metastatic NSCLC Patients With HER2 Alterations
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Not yet recruiting
NCT04401059 2023-12-27
SELECT-2
Hangzhou Normal University
Phase 4 Recruiting
NCT06102928 2023-10-26
A Clinical Study of the Combination of Anlotinib and Aumolertinib in the First-line Treatment of Advanced NSCLC With EGFR 21L858R Mutation
Kunming Medical University
Phase NA Recruiting
NCT06043973 2023-09-21
Almonertinib Combined With Anlotinib as First-line Treatment for Advanced Non-small Cell Lung Cance
Qianfoshan Hospital
Phase 3 Recruiting
NCT05994339 2023-08-29
Radiotherapy Combined With Almonertinib for Stage III EGFR-Mutated Lung Cancer
Laibin People's Hospital
Phase 2/3 Unknown
NCT05826483 2023-04-24
Almonertinib in the First-line Treatment of Patients of NSCLC With Poor Performance Status
Guangzhou Institute of Respiratory Disease
Phase 1 Unknown
NCT04922138 2023-04-21
APPOINT
Shanghai Chest Hospital
Phase 2 Unknown
NCT05800223 2023-04-05
Armatinib Alone or in Combination With SRT for Brain Metastases EGFR-mutated Non-small Cell Lung Cancer
Shanghai Cancer Hospital, China
Phase 3 Recruiting
NCT04519983 2023-03-20
Efficacy of SRT as Salvage Therapy in Patients With Brain Oligo-progression of EGFR-mutant Non-small Cell Lung Cancer After Failure of the Third-generation EGFR-TKIs
Shanghai Cancer Hospital, China
Phase 2 Unknown
NCT05430386 2023-02-14
Study of HS-10241 in Combination With Almonertinib in Patients With Locally Advanced or Metastatic NSCLC
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Phase 1 Unknown
NCT02981108 2023-01-23
A Study to Evaluate Safety, PK and Efficacy of HS-10296 in Patients With NSCLC
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Phase 1/2 Unknown
NCT03849768 2023-01-20
A Study to Evaluate Safety and Efficacy of HS-10296 as First-Line Treatment in Patients
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Phase 3 Unknown
NCT04951635 2022-06-16
A Phase III Study to Assess the Effects of Almonertinib Following Chemoradiation in Patients With Stage III Unresectable Non-small Cell Lung Cancer
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Phase 3 Recruiting
NCT04762459 2022-02-24
APEX
ChineseAMS
Phase 3 Enrolling by invitation
NCT05223595 2022-02-04
A Study of Gentuximab in Combination With Almonertinib in EGFR Mutation-positive Metastatic NSCLC
Changchun GeneScience Pharmaceutical Co., Ltd.
Phase 1 Unknown
NCT04755738 2021-09-05
MWA
Qianfoshan Hospital
Phase 2 Unknown
NCT04978753 2021-07-27
the Efficacy and Safety of Anlotinib Combined With Almonertinib in the First-line Treatment of Patients With Brain Metastases From EGFR Mutation-positive Non-small Cell Lung Cancer
Sun Yat-sen University
Phase 2 Unknown
NCT04951648 2021-07-07
A Phase III Study to Assess the Efficacy and Safety of Almonertinib Versus Platinum-based Chemotherapy as First-line Therapy in Patients With Locally Advanced or Metastatic NSCLC Harbouring Uncommon EGFR Mutation
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Phase 3 Unknown
NCT04952168 2021-07-07
Combination of Almonertinib and Concurrent Chemoradiotherapy in Unresectable Stage III NSCLC
Tongji Hospital
Phase 2 Unknown
NCT04944069 2021-06-29
ATTRACT
Second Affiliated Hospital of Nanchang University
Phase NA Unknown
NCT04905550 2021-06-02
Almonertinib Combined With Cerebral Radiation Treat Brain Metastases From EGFR Positive NSCLC
Chongqing University Cancer Hospital
Phase 2 Unknown
NCT04882345 2021-05-11
ACTIVE
Shanghai Chest Hospital
Phase 2 Unknown
NCT04500704 2020-08-05
ACROSS1
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 3 Unknown
NCT04500717 2020-08-05
ACROSS2
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 3 Unknown
NCT04455594 2020-07-02
ANSWER
The First Affiliated Hospital of Guangzhou Medical University
Phase 2 Unknown